Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01067846
Other study ID # 111989
Secondary ID R21DA025243
Status Completed
Phase N/A
First received February 10, 2010
Last updated October 31, 2013
Start date June 2010
Est. completion date January 2012

Study information

Verified date October 2013
Source University of Arkansas
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

For this project, the investigators are interested in exploring a new way to extend and maintain drug abstinence in people who are addicted to crack cocaine. This study will combine a medication called D-Cycloserine (DCS) and weekly cognitive behavioral therapy (CBT) to assess whether the combination will enhance people's ability to stay clean (drug free) for longer periods of time.

One of the greatest risks for drug relapse is drug craving. Oftentimes drug craving occurs when a person is confronted with stressors and reminders of past drug use behavior. DCS has been shown to enhance the learning of new information. By administering DCS prior to learning new techniques such as how to cope with drug craving and drug-use reminders, it is possible that patients can be more successful at living a drug free life for a longer period of time.

In addition to exploring this model behaviorally, the investigators will explore changes that may occur in the brain before and after the therapy/medication intervention. A technique called MRI (Magnetic Resonance Imaging) will be used to identify areas of the brain that are being activated during an attention task. Areas of neural activation will be assessed at study entry, end of therapy (4-week endpoint) and one month following completion of the treatment program.


Description:

Primary Hypothesis:

Enhancing glutamatergic neurotransmission with DCS facilitates CBT-related relapse prevention by potentiating the behavioral and neural representation of the diminished drug motivation associated with cocaine cues.

Specific Aims:

1. Determine if the short-term oral administration of DCS relative to placebo prior to CBT sessions facilitates cocaine abstinence and functional recovery, and reduces cocaine craving in treatment-seeking cocaine addicts.

2. Determine if DCS administration relative to placebo facilitates CBT-related decreases in the behavioral and neural response to conditioned cocaine cues.


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date January 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Eligible subjects must be cocaine-dependent persons between 18 and 65 years

Exclusion Criteria:

- Any current Axis-I psychiatric diagnosis other than cocaine or alcohol dependence or nicotine use

- Any current or prior neurological disease, history of a major medical illness, or current use of psychotropic medications

- Positive history of loss of consciousness of greater than 10 min

- Significant current or prior cardiovascular disease (hypertension, arrhythmias) that is not medically stable

- History of hospitalization within the previous six months for a medical illness

- Deafness, blindness or other significant sensory impairment.

- Contraindications for D-cycloserine and magnetic resonance imaging.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Seromycin (D-cycloserine, DCS)
250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
Placebo
Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
Behavioral:
Computerized Cognitive Behavioral Therapy
All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.

Locations

Country Name City State
United States Psychiatric Research Institute (PRI) (Center for Addiction Research (CAR) and Brain Imaging Research Center (BIRC)) University of Arkansas for Medical Sciences Little Rock Arkansas

Sponsors (2)

Lead Sponsor Collaborator
University of Arkansas National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Drug Abstinence During Treatment and at Follow up Visits Percentage of the overall number of drug abstinences of participants measured by urine drug testing Participants provided urine samples for drug testing during treatment which occurred 3 times per week for 4 weeks, at the end of treatment, and at a 1 and 2 month follow up visit No
Primary Treatment Retention - Number of Visits During Treatment Number of treatment visits attended prior to discontinuation of treatment Treatment sessions included 3 visits per week for 4 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04336293 - sTMS for Substance Use-disordered Veterans N/A
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT01822587 - Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving Phase 2
Completed NCT01601743 - Exercise as a Behavioral Treatment for Cocaine Dependence N/A
Completed NCT02563769 - Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study Phase 1
Completed NCT01651377 - Pramipexole as a Treatment for Cocaine Dependence Phase 1
Completed NCT02768441 - Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots Early Phase 1
Completed NCT02626494 - Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Phase 4
Recruiting NCT02892851 - Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction. N/A
Not yet recruiting NCT01319214 - Reducing Drug Craving Memories N/A
Recruiting NCT01259362 - Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients Phase 2
Completed NCT01211418 - Integrative Meditation (IM) for Cocaine Addiction N/A
Recruiting NCT03423667 - Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction Phase 2
Completed NCT01887366 - Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects Phase 2
Completed NCT01984177 - Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence N/A
Completed NCT01337297 - Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction Phase 1/Phase 2
Completed NCT01651364 - A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence Phase 1
Recruiting NCT03018236 - Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Phase 4
Completed NCT01929343 - Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Phase 2
Completed NCT01281202 - Vigabatrin for the Treatment of Cocaine Dependency Phase 2/Phase 3